INTRODUCTION:

Nipah virus is one of which, Efforts have been made to study and research potential epidemics that are more severe and causing pathogens in the current covid-19 pandemic¹

The Nipah virus is also known as Nipah bug cephalitis which produces a original species, Henipaviral. Kaw Bing Chua discovered and identified in 1999 later an epidemic of cephalitis in pig breeders and exported to Malaysia and Singapore²

The initial two Nipah virus epidemic in India, reported in 2001³ and 2007 took place in West Bengal. The primary human NIV infection was raised to be link with trade swine and it verified that NIV maybe detected from the nose and oropharynx of pig^4,5,6,7

On the WHO priority list NIV is first pathogens which cause probably cause epidemic requiring crucial investigate and expansion achievement⁸same as to lyssaviruses, filovirus, corona virus and it is interrelated with Hendra virus NIV is certainly presented by pteroid bats^9,10

In Melanesia south and southeast Asia and Sub-Saharan Africa Fruit bats are found which is the essential storage of Nipah virus and most annually explosion of NIV infection go to arise during south and southeast Asia^10,11Scientists and public health officials soon discovered that the Nipah virus had the capability to spread easily from one person to another¹²NIV is one of the riskiest emergent bugs, largely because of it has ability to spread straightforwardly from individual to another.¹³

HISTORY:

1. Malaysia: In September 1998, In Malaysia the initial human cases of Nipah virus surfaced midst pig farmers an epidemic Initially the cases were misidentified as Japanese with pigs and the incidence in adults were not typical of infections caused by Japanese encephalitis agents. Encephalitis However, the mode of transmission through direct contact⁶

A new virus (NIV) was discovered in march 1999 which is found in cerebrospinal fluid of a patient from Sungai Nipah village. This epidemic resulted in 283 symptomatic cases and led to 109 deaths¹⁴

In Malaysia, it was discovered that pteropods bats served as the primary reservoir of infection. The transmission to pigs occurred when they consumed fruits that had been previously bitten by these bats, thus acting as amplifying hosts for the infection.¹⁵

2. Singapore: In march 1099 Singapore expressed an explosion of disease among slaughterhouse workers with 11 cases and one death¹⁶

The meatpackers who managed the pigs important for Malaysia infected through Niv. All of 11 cases one was lethal¹⁶ in the intermediate age group of 24 to 60 years old, was affected for 44 years. All the patient were chines except for one who was Indian. The infection connects both ventilatory system and CNS¹⁶

3. Bangladesh: In Bangladesh the main source of Niv transmission which is shown in the research it occurs when eating an infected raw palm date and fruits^17,18

Domestic animals like pig can also pass on diseases from bats to humans. In Bangladesh, pigs have been found to have a high number of antibodies against Nipah virus indicating they may have been exposed to the virus ¹⁹

4. India: In 2001, Siliguri, West Bengal, experienced a significant outbreak with 45 lethal and 66 probables. Then, in 2007, Nadia district, also in West Bengal, faced a less epidemic with 100% death rate and five cases²⁰

In May 2018, Kerala experienced a severe epidemic of NIV infection, with 18 cases reported. This strain was marked by symptoms such as acute respiratory syndrome and encephalitis. The death rate was alarmingly high, with at least 17 deaths reported, surpassing a staggering 90%²¹

Undoubtedly, the Kerala State Health Department said on September 4, 2021, that Kozhikode, Kerala, India, had experienced a fifth Nipah Virus pandemic.²²

In India, all epidemic of Nipah Virus have shown human-to human transmission. While the epidemiology of Nipah virus in India is similar to that in Bangladesh; thus far, only three epidemics have been documented. Consequently, conclusive proof is not available at this time.

5. Philippines:

2014 saw an outbreak of NIV infection in the Philippines. With 17 cases validated, 82% of cases resulted in a death.²³

This was the first case of NIV infection being connected to horse slaughter and horse meat consumption, even though some cases were caused by human-to-human transmission. Additionally, it has been established that eating horsemeat lately caused illness and death in horses and other domestic animals.²³The most likely source of the infection in the horse was fruit bats.²³

Transmission of NIV:

1. Human to Human Transmission:

The Nipah virus mostly spreads from person to person through direct contact with infected patients and their bodily fluids, according to research conducted during the epidemic in Bangladesh.²⁴

The 2003 study did not completely rule out the possibility of external infection, but it did raise the prospect of human-to-human transmission within shared residences due to the virus's presence. Most likely, this would occur through respiratory channels. Nevertheless, uncertainties persisted as hospital employees who interacted with patients did not report any infections.²⁵

Siliguri, West Bengal, was the site of the first NIV epidemic in India (2001). An examination revealed that respiratory secretions could spread from person to person²⁶.

The pandemic in India's West Bengal and Kerala and Bangladesh has comparable epidemiology’s, indicating that the virus can spread from person to person without the need for a mediating host²⁷

In both home and nosocomial settings, human-to-human transmission through respiratory droplets has been documented. NIV has been isolated from urine and respiratory samples of infected persons.²⁸

2. Animal as a source of Nipah virus:

The identification of NIV has been made in Malaysia in the homelands of two pteropod species: Lyle and vampires.²⁹

Fruits eaten only partially or contaminated by NIV-infected bats are the main ways that the virus spreads from bats to pigs.²⁶

When comparing the Nipah virus (NIV) gene discovered in infected bats to that of patients in Bangladesh, Malaysia, and Cambodia, it is evident that bats were the main source of human infection throughout the epidemic. Either eating fruit tainted with bat saliva or breathing in aerosols containing tainted urine or saliva droplets are most likely the routes via which this transmission happened³⁰

However, the finding of NIV in individuals who had no contact with pigs prompted researchers to look for more possible hosts of the virus that might endanger people. After tests on pigs, dogs, birds, and bats following the outbreaks in Bangladesh, no virus was discovered in any of the animal species, and only antibodies were found in bats, indicating that bats could be a possible source of unintentional infection. Nicotine entered the human body by a number of distinct pathways, including the respiratory and central nervous systems (CNS). Dendritic, epithelial, and endothelial cells are involved in the viraemic spread of the infection. Researchers have determined that the human body contains important nicotine (NIV) receptors called ephrin B2 and ephrin B3.²⁶

If humans come into contact with animals other than bats, including pigs, horses, dogs, or cats, the likelihood of infection increases³¹

Pathogenesis: Non-invasive ventilation (NIV) is seen in the bronchiole epithelial cells during the early stages of human collapse. The bronchi and alveoli can also show signs of viral antigen presence, particularly in experimental animal models when the main targets are the bronchi's epithelial cells and type II pneumocytes.³²

The central nervous system (CNS) and respiratory system were two of the many pathways that nicotine entered the human body. Endothelial cells, epithelial cells, and dendritic cells are all involved in the viraemic propagation of the infection. Scholars have discovered³³

A study examining 32 sufferers of Nipah virus (NIV) infection during the starting outbreak in Malaysia and Singapore in 1998-1999 explain that, on average, patients were hospitalized approximately 3.3 days after the onset of fever. Unfortunately, the mean time from the onset of fever to death was only 9.5 days.³⁴

The strain of NIV responsible for the recurrent outbreaks in Bangladesh (NIV-B) is distinct from the strain isolated in Malaysia and Singapore (NIV-M) and has been associated with different clinical and epidemiological findings³⁵

It has been discovered that NIV enters the central nervous system through immune cells in circulation, especially monocytic and immature dendritic cells³⁶.

Although NIV could infect these cells, the virus could not replicate well in them. But NIV-infected immune cells managed to penetrate the blood-brain barrier in vitro and concentrated their infection of susceptible cells, mimicking the appearance of neuronal infections. As a result, both NIV-infected humans and animals' brains had localized lesions, as reported in sources^37,38. Within a week of infection, the virus then swiftly moved to other organs, affecting the liver, heart, spleen, and kidneys.^35,39,40

Two main Nipah virus (NIV) strains have been found to be circulating in pigs in Malaysia: one in the country's north and another in its south. At least two cases of viral introduction into pig populations have been documented.⁴¹

Although the virus is widespread throughout the body, brain microvascular arteries are frequently its target.

To battle the virus's impacts, especially those in the brain, and to create effective antiviral medicines, more study is necessary to better understand how the virus⁴²

Clinical Feature:

The primary clinical signs, characteristic symptoms and severe symptoms are shown in Table⁴³

NIV can incubate for four to twenty-one days. NIV is extremely deadly and mostly causes acute encephalitis and respiratory illnesses. Only a small portion of those with the infection exhibit illness symptoms.⁴⁴

Of course, serious respiratory problems are not the only neurological symptoms associated with an NIV infection. During epidemics in, diagnoses of coughs, colds, shortness of breath, and in severe cases, acute respiratory distress syndrome, were particularly common.^45,46,29,47

The (CDC) recommendations state that real-time polymerase chain reaction (RT-PCR) from the throat and nasal swabs, cerebrospinal fluid, urine, and blood can be used to diagnose a patient with a clinical history of NIV during the acute phase. Whilst ELISA was used to identify antibodies (IgG and IgM)⁴⁸

Diagnosis:

The Nipah virus is diagnosed using a variety of techniques (NIV). A technique for doing this is to isolate the virus in Vero cells, and after three days, observe cytotoxic effects such as syncytial development and cell death. Cerebrospinal fluid (CSF), respiratory swabs in viral transport medium, blood, and urine are samples from which NIV can be extracted. To guarantee safety, nevertheless, every testing method needs to be overseen in a Biosafety Level 4 (BSL-4) laboratory.^20,29

Novel influenza viruses (NIV) are usually diagnosed in facilities that are classified as having Biosafety Level 3 (BSL3) or BSL4. Molecular assays, serological assays, immunohistochemistry, histopathology, viral isolation, and neutralization are among the diagnostic procedures used to identify NIV. These techniques are employed for scientific and public health objectives in order to characterize and illustrate new influenza viruses.⁴⁹

The anti-NIV specific IgM was found using the fastest ELISA assay, while the IgG antibody was found using an accidental IgG ELISA.^50,51

Low platelet and white blood cell counts are referred to as thrombocytopenic leukopenia in patients with NIV encephalitis. Their liver function tests may also reveal anomalies that point to possible liver impairment.⁵²

In accordance with CDC guidelines, RT-PCR and viral isolation techniques from throat and nasal swabs, cerebrospinal fluid, urine, and blood samples can be used to diagnose a patient with a clinical history of NIV during the acute phase. Eventually, diagnosis can also be made by antibody exposure by ELISA (IgG and IgM)⁴⁸

Treatment and Prevention:

In 2015, a study evaluating the behaviour of people consuming raw date palm sap, found that awareness of NIV was very low among them and surprisingly even people who were aware of this virus were just as likely to consume it as people who did not⁵³

Due to the absence of an effective drug against NIV, the administrations of patients are limited to supportive and prophylactic treatment^54,29

The antimalarial drug chloroquine exhibits completely preventing NIV in cell cultures, which could not be confirmed in animal model^20,21,48

Favipiravir (T-705), a purine analogue preventing RNA-dependent RNA polymerase worked to clinical trials for Ebola and different types of influenza antivirals have also show effectiveness against NIV in Syrian hamster animal models^55,56

Prevention of person-to-person transmission includes the implementation of infection control practices such as isolation of patients, use of personal protective equipment and good hand hygiene practices. Contacts recognised through contact tracing are tested and kept under examination until they test negative. Hospital surfaces have been found to be infected by NIV around patients⁵⁷

It’s important to washing or peeling of fruits and washing hand while having fruits and making meals should be followed²⁴

That’s why, healthcare professionals are guidance to treat any Nipah like symptoms as a complete emergency to inhibit the expand of the virus⁴⁸

Vaccines:

A Lot’s of vaccine crucial have been developed for NIV, several of which have been tested in animal models. The most studied submission has been a subunit vaccine based on G glycoprotein (SG) of NIV and HEV. HEV-SG elicits a cross-protective immune response against both HEV and NIV⁵⁸

The first and only licensed preventive treatment for the NIV which is currently available is the lastly mentioned Equifax HEV. It was introduced in Australia in 2012 and is an equine vaccine⁵⁹

Manged two studies on this NIV vaccine. The first one study appear that a single dose of vaccination was productive, and the second one appear that the period of 7 days after the first dose was productive in protecting African green monkey (AGM) from the refused form of NIV. Studies manged in an animal model similar to the human organism–the AGM model confirm the effectiveness of a single dose of this vaccine, which may represent the basis for its possible use in the event of immediate epidemic of NIV infection⁶⁰

For humans, the HEV SG subunit vaccine is newly in clinical development as an emergency vaccine for NIV epidemic⁶⁰

Passive immunisation using a human monoclonal antibody that goal the Nipah g glycoproteins has been classify in within the ferret model as post liability prophylaxis⁶¹

Monoclonal antibody (m102.4) against the G glycoprotein of the NIV, if taken pre-susceptible or up to 10 h after susceptible has seen to inhibit the disease condition in ferrets^62,63

In the Syrian hamster model study, HEV SG mRNA LNP seen promising cross-protective results against NIV, with 70% of the animals surviving a fatal NIV challenge⁶⁴

A subunit vaccine using the hendra G larger molecules or protein was begin to make cross -protective antibodies in cases of henipaviral and NIV has been used in monkeys to shield against hendra virus, completeits potential to be used in humans has not been prepared⁶⁵The vaccine has been seen to make short protecting antibodies in case of NIV and hendra virus and provide great potential for henipaviral protection in humans as well...⁶⁶

Vaccine vectors included in different studies are vascular stomatitis virus (VSV), Rabies virus (RABV), Canary pox vaccine virus (CNPV ALVAC), Adeno associated virus (AAD), Measles virus (MV), Venezuelan equine encephalitis virus (VEE) and Newcastle disease virus (NDV)^67,68more lasting protection after vaccination with sG HeV was seen in the ferret model, when ferrets were surely protected from death Nipah virus challenge more than a year after receiving two doses of sG HeV with adjuvant.⁵⁹

Fusion preventor that block the expression of Ephrin-B2 could be used in future vaccines or therapeutic agents of clinical benefit⁶⁹

Appearance of the Nipah virus glycoprotein G from an adeno-associated virus also caused in whole protection of hamsters with a single intramuscular vaccination⁷⁰

These recombinant viruses express the F or G glycoproteins on their surface^71,35A mammalian cell-derived virus-like particlevaccine has also been produced⁷²

The analysis discovery from candidate vaccine studies have provided crucial insights for developing vaccines against NIV (novel influenza virus) infections. These studies point out the importance of viral glycoproteins in stimulating neutralizing antibodies, which serve as vaccine candidates to safeguard against the disease. Moreover, these vaccines hold the potential to offer cross-protection against closely related viruses. This underscores the importance of targeting specific viral components to enhance vaccine ability and develop protection against related pathogens

CONCLUSIONS:

Similar in high morbidity and motility in both humans and animals, NIV is a zoonotic virus. This is South India's first documented Niv outbreak. This review enumerates the common knowledge about Niv pathogenesis, including how the net and adaptive immune response are triggered by NIV infection. The absence of a recognized vaccination or medication that is effective in preventing the spread of Niv in the human population is a significant factor in this worry. Niv causes respiratory infections and encephalitis in people.

REFERENCES:

1. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG, Zaki SR, Paul G, Lam SK, Tan CT. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. The Lancet. 1999 Oct 9; 354(9186): 1257-9. https://doi.org/10.1016/S0140-6736(99)04299-3

2. Kulkarni DD, Tosh C, Venkatesh G, Senthil Kumar D. Nipah virus infection: current scenario. Indian Journal of Virology. 2013 Dec; 24(3): 398-408. DOI 10.1007/s13337-013-0171-y.

3. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, Mishra AC. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerging infectious diseases. 2006 Feb; 12(2): 235. DOI: 10.3201/eid1202.051247

4. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh WJ, Goldsmith CS. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000 May 26; 288(5470): 1432-5. DOI: 10.1126/science.288.5470.1432

5. Ensuring M. New viruses fingered in Malaysia epidemic DOI: 10.1126/science.284.5413.407

6. Centres for Disease Control and Prevention (CDC. Update: outbreak of Nipah virus--Malaysia and Singapore, 1999. MMWR. Morbidity and Mortality Weekly Report. 1999 Apr 30; 48(16): 335-7. PMID: 10366143

7. 8 Paton NI, Leo YS, Zaki SR, Auch us AP, Lee KE, Ling AE, Chew SK, Ang B, Rollin PE, Umapathi T, Sang I. Outbreak of Nipah-virus infection among abattoir workers in Singapore. The Lancet. 1999 Oct 9; 354(9186): 1253-6. DOI: 10.1016/S0140-6736(99)04379-2

8. Shariff M. Nipah virus infection: A review. Epidemiology and Infection. 2019;147: e95. DOI: 10.1017/S0950268819000086

9. Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019 Jan 9; 11(1): 41. DOI: 10.3390/v11010041

10. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Rahman SA, Hughes T, Smith C, Field HE, Dastak P. Pteropod bats are confirmed as the reservoir hosts of heptaverines: a comprehensive experimental study of virus transmission. The American Journal of Tropical Medicine and Hygiene. 2011 Nov 11; 85(5): 946. DOI: 10.4269/ajtmh.2011.10-0567

11. Chow VT, Tambiah PA, Yeo WM, Phoon MC, Howe J. Diagnosis of Nipah virus encephalitis by electron microscopy of cerebrospinal fluid. Journal of Clinical Virology. 2000 Oct 1; 19(3): 143-7. Doi: 10.1007/s13337-013-0171-y

12. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, Mishra AC. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerging Infectious Diseases. 2006 Feb; 12(2): 235. DOI: 10.3201/eid1202.051247

13. World Health Organization. List of Blueprint priority diseases. R&D Blueprint. World Health Organization. 2018 Nov. DOI: 10.1016/j.antiviral.2018.09.009

14. Chua KB. Nipah virus outbreak in Malaysia. Journal of Clinical Virology. 2003 Apr 1; 26(3): 265-75. DOI: 10.1016/s1386-6532(02)00268-8

15. Rahman SA, Hassan SS, Oliva KJ, Mohamed M, Chang LY, Hassan L, Saad NM, Shoham SA, Mamat ZC, Naim MS, Epstein JH. Characterization of Nipah virus from naturally infected Pteropods vampires’ bats, Malaysia. Emerging Infectious Diseases. 2010 Dec; 16(12): 1990 Doi: 10.3201/eid1612.091790

16. Paton NI, Leo YS, Zaki SR, Auch us AP, Lee KE, Ling AE, Chew SK, Ang B, Rollin PE, Umapathi T, Sang I. Outbreak of Nipah-virus infection among abattoir workers in Singapore. The Lancet. 1999 Oct 9; 354(9186): 1253-6. DOI: 10.1016/S0140-6736(99)04379-2

17. Wahed F, Kader SA, Nessa A, Mahamud MM. Nipah virus: an emergent deadly Paramyxovirus infection in Bangladesh. Journal of Bangladesh Society of Physiologist. 2011; 6(2): 134-9... https://doi.org/10.3329/jbsp.v6i2.9764

18. Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, Gurley ES, Rollin PE, Lo MK, Comer JA, Lowe L. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector-Borne and Zoonotic Diseases. 2012 Jan 1; 12(1): 65-72. DOI: 10.1089/vbz.2011.0656

19. Chowdhury S, Khan SU, Cramer G, Epstein JH, Broder CC, Islam A, Peel AJ, Barr J, Dastak P, Wang LF, Luby SP. Serological evidence of henipaviral exposure in cattle, goats and pigs in Bangladesh. Plops Neglected Tropical Diseases. 2014 Nov 20; 8(11): e3302. Doi: 10.1371/journal.pntd.0003302

20. Shariff M. Nipah virus infection: A review. Epidemiology and Infection. 2019; 147: e95. DOI: 10.1017/S0950268819000086

21. Ambat AS, Zubair SM, Prasad N, Pundir P, Rajwar E, Patil DS, Manga P. Nipah virus: A review on epidemiological characteristics and outbreaks to inform public health decision making. J Infect Public Health. 2019 Sep-Oct; 12(5): 634-639. Doi: 10.1016/j.jiph.2019.02.013

22. Yadav PD, Sahay RR, Balakrishnan A, Mohandas S, Radhakrishnan C, Gokhale MD, Balasubramanian R, Abraham P, Gupta N, Sugunan AP, Khobragade R. Nipah virus outbreak in Kerala State, India amidst of COVID-19 pandemic. Frontiers in Public Health. 2022 Feb 17; 10: 818545. Doi: 10.3389/fpubh.2022.818545

23. Ching PK, de Los Reyes VC, Sausalito MN, Tayag E, Columna-Vingo AB, Malbasa Jr FF, Bolo Jr GC, Sever JJ, Eagles D, Playford G, Dreger E. Outbreak of henipaviral infection, Philippines, 2014. Emerging Infectious Diseases. 2015 Feb; 21(2): 328. Doi: 10.3201/eid2102.141433

24. Montgomery JM, Hossain MJ, Gurley E, Carroll DS, Crosier A, Berthe rat E, Asgari N, Furmenty P, Keeler N, Comer J, Bell MR. Risk factors for Nipah virus encephalitis in Bangladesh. Emerging Infectious Diseases. 2008 Oct; 14(10): 1526 Doi: 10.3201/eid1410.060507

25. Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda M, Rupprecht C, Bresee J, Bierman RF. Nipah virus encephalitis reemergence, Bangladesh. Emerging Infectious Diseases. 2004 Dec; 10(12): 2082. Doi: 10.3201/eid1012.040701

26. Luby SP. The pandemic potential of Nipah virus. Antiviral Research. 2013 Oct 1; 100(1): 38-43. DOI: 10.1016/ j.antiviral.2013.07.011

27. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, Molla MA, Carroll DS, Ksiazek TG, Rota PA, Lowe L. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerging Infectious Diseases. 2007 Jul; 13(7): 1031. DOI: 10.3201/eid1307.061128

28. Kenmoe S, Demanou M, Bigan JJ, Kengne CN, Modifying AF, Simo FB, Elango S, Sadegh-Mba SA, Nojoom R. Case fatality rate and risk factors for Nipah virus encephalitis: A systematic review and meta-analysis. Journal of Clinical Virology. 2019 Aug 1; 117: 19-26. DOI: 10.1016/j.jcv.2019.05.009

29. Sharma V, Kaushik S, Kumar R, Yadav JP, Kaushik S. Emerging trends of Nipah virus: A review. Reviews in Medical Virology. 2019 Jan; 29(1): e2010. Doi: 10.1002/rmv.2010

30. Yadav PD, Shete AM, Kumar GA, Sar kale P, Sahay RR, Radhakrishnan C, Lakra R, Pardeshi P, Gupta N, Gyanashekar RR, Rajendran VR. Nipah virus sequences from humans and bats during Nipah outbreak, Kerala, India, 2018. Emerging Infectious Diseases. 2019 May; 25(5): 1003. Doi: 10.3201/ eid2505.181076

31. McEntire CR, Song KW, McInnis RP, Rhee JY, Young M, Williams E, Wilbekin LL, Nolan N, Nagy AM, Gluckstein J, Mukerji SS. Neurologic manifestations of the World Health Organization's list of pandemic and epidemic diseases. Frontiers in Neurology. 2021 Feb 22; 12: 634827. DOI: 10.3389/ fneur.2021.634827

32. Stachowiak B, Wingert HM. Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells. Plops One. 2012 Jan 27; 7(1): e30855. Doi: 10.1371/journal.pone.0030855, PMID 22303463

33. Mathieu C, Horvat B. Henipaviral pathogenesis and antiviral approaches. Expert Review of Anti-infective Therapy. 2015 Mar 4; 13(3): 343-54. DOI: 10.1586/14787210.2015.1001838

34. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh WJ, Goldsmith CS. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000 May 26; 288(5470): 1432-5. DOI: 10.1126/science.288.5470.1432

35. Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW. Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Scientific Reports. 2016 Aug 3; 6(1): 30916. DOI: 10.1038/srep30916

36. Tiong V, Shu MH, Wong WF, Abubakar S, Chang LY. Nipah virus infection of immature dendritic cells increases its trans endothelial migration across human brain microvascular endothelial cells. Frontiers in Microbiology. 2018 Nov 13; 9: 421816. DOI: 10.3389/fmicb.2018.02747

37. Liu J, Coffin KM, Johnston SC, Babka AM, Bell TM, Long SY, Honko AN, Kuhn JH, Zeng X. Nipah virus persists in the brains of nonhuman primate survivors. JCI Insight. 2019 Jul 7; 4(14). DOI: 10.1172/jci.insight.129629

38. Wong KT, Robertson T, Ong BB, Chong JW, Yaw KC, Wang LF, Alsford AJ, Tannenberg A. Human Hendra virus infection causes acute and relapsing encephalitis. Neuropathology and Applied Neurobiology. 2009 Jun; 35(3): 296-305. DOI: 10.1111/j.1365-2990.2008. 00991.x

39. Geisbert TW, Daddario-DiCaprio KM, Hickey AC, Smith MA, Chan YP, Wang LF, Mutawalli JJ, Geisbert JB, Bossart KN, Broder CC. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. Plops One. 2010 May 18; 5(5): e10690. DOI: 10.1371/journal.pone.0010690

40. Guillaume V, Wong KT, Looi RY, Georges-Courbet MC, Barrot L, Buckland R, Wild TF, Horvat B. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. Virology. 2009 May 10; 387(2): 459-65. DOI: 10.1016/j.virol.2009.03.001

41. Abubakar S, Chang LY, Ali AM, Sharifah SH, Yusoff K, Ramrod Z. Isolation and molecular identification of Nipah virus from pigs. Emerging Infectious Diseases. 2004 Dec; 10(12): 2228. Doi: 10.3201/eid1012.040452

42. Mathieu C, Horvat B. Henipaviral pathogenesis and antiviral approaches. Expert Review of Anti-infective Therapy. 2015 Mar 4; 13(3): 343-54. DOI: 10.1586/14787210.2015.1001838

43. Lo MK, Rota PA. The emergence of Nipah virus, a highly pathogenic paramyxovirus. Journal of Clinical Virology. 2008 Dec 1; 43(4): 396-400. DOI: 10.1016/j.jcv.2008.08.007

44. Parashar UD, Sunn LM, Ong F, Mounts AW, Arif MT, Ksiazek TG, Kamaluddin MA, Mustafa AN, Kaur H, Ding LM, Othman G. Case-control study of risk factors for human infection with a new zoonotic paramyxovirus, Nipah virus, during a 1998–1999 outbreak of severe encephalitis in Malaysia. The Journal of Infectious Diseases. 2000 May 1; 181(5): 1755-9 DOI: 10.1086/315457

45. Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, Sari SA, Wong KT, Abdullah BJ, Chua KB, Lam SK. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. New England Journal of Medicine. 2000 Apr 27; 342(17): 1229-35. Doi: 10.1056/ NEJM200004273421701

46. Chua KB. Nipah virus outbreak in Malaysia. Journal of Clinical Virology. 2003 Apr 1;26(3):265-75.

47. Sharma V, Kaushik S, Kumar R, Yadav JP, Kaushik S. Emerging trends of Nipah virus: A review. Reviews in Medical Virology. 2019 Jan; 29(1): e2010. Doi: 10.1002/rim. 2010

48. Thomas B, Chandran P, Lilabai MP, George B, Sivakumar CP, Jayadev VK, Bindu V, Rajasi RS, Vijayan B, Mohandas A, Hafeez N. Nipah virus infection in Kozhikode, Kerala, South India, in 2018: epidemiology of an outbreak of an emerging disease. Indian Journal of Community Medicine. 2019 Oct 1; 44(4): 383-7. Doi: 10.4103/ijcm.IJCM_198_19

49. Ochan RK, Batra S, Shaikh A, Asad A. Nipah virus-the rising epidemic: a review. Inez Med. 2019 Jun 1; 27(2): 117-27. Shariff M. Nipah virus infection: A review. Epidemiology and Infection. 2019; 147: Doi: 10.3389/fmicb.2021.811157

50. Mazzola LT, Kelly-Cirino C. Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia. BMJ Global Health. 2019 Feb 1; 4(Supple 2): e001118. DOI: 10.1136/bmjgh-2018-001118

51. Abdullah S, Tan CT. Henipaviral encephalitis. Handbook of Clinical Neurology. 2014 Jan 1; 123: 663-70. DOI: 10.1016/B978-0-444-53488-0.00032-8

52. Ali R, Mounts AW, Parashar UD, Sahani M, Lye MS, Isa M, Balathevan K, Arif T, Ksiazek TG. Nipah virus infection among military personnel involved in pig culling during an outbreak of encephalitis in Malaysia, 1998-1999. Emerging Infectious Diseases. 2001 Jul 1; 7(4): 759-. DOI: 10.3201/eid0704.010433

53. Lim CC, Lee WL, Leo YS, Lee KE, Chan KP, Ling AE, Oh H, Auch us AP, Paton NI, Hui F, Tambiah PA. Late clinical and magnetic resonance imaging follow up of Nipah virus infection. Journal of Neurology, Neurosurgery and Psychiatry. 2003 Jan 1; 74(1): 131-3. Doi: 10.1016/S0002-9440(10)64493-8

54. Nahar N, Paul RC, Sultana R, Gurley ES, Garcia F, Abedin J, Sumon SA, Banik KC, Acidizing M, Rimi NA, Rahman M. Raw sap consumption habits and its association with knowledge of Nipah virus in two endemic districts in Bangladesh. Plops One. 2015 Nov 9; 10(11): e0142292. Doi: 10.1371/journal.pone.0142292

55. Chakraborty S, Deb B, Barbhuiya PA, Uddin A. Analysis of codon usage patterns and influencing factors in Nipah virus. Virus Research. 2019 Apr 2; 263: 129-38. Doi: 10.1016/j.virusres.2019.01.011

56. Dawes BE, Alvera B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Scientific Reports. 2018 May 15; 8(1): 7604. DOI: 10.1038/s41598-018-25780-3

57. Schaffer O, Hill T, Ikegami T, Juelich TL, Smith JK, Zhang L, Perez DE, Atkins C, Park A, Lawrence WS, Sivasubramanian SK. Experimental infection of Syrian hamsters with aerosolized Nipah virus. The Journal of Infectious Diseases. 2018 Oct 5; 218(10): 1602-10. Doi: 10.1093/indies/jiy357

58. 15. Hassan MZ, Sazid HM, Luby SP, Sturm-Ramirez K, Bhuiyan MU, Rahman MZ, Islam MM, Strother U, Sultana S, Kafi MA, Dastak P. Nipah virus contamination of hospital surfaces during outbreaks, Bangladesh. 2013–2014. Emerging Infectious Diseases. 2018 Jan; 24(1): Doi: 10.3201/eid2401.161758

59. Pallister JA, Klein R, Ark installs R, Haining J, Long F, White JR, Payne J, Feng YR, Wang LF, Broder CC, Middleton D. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virology Journal. 2013 Dec; 10: 1-7. DOI: 10.1186/1743-422X-10-237

60. Wong KT, Shieh WJ, Kumar S, Noraini K, Abdullah W, Guarneri J, Goldsmith CS, Chua KB, Lam SK, Tan CT, Goh KJ. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. The American Journal of Pathology. 2002 Dec 1; 161(6): 2153-67. DOI: 10.1016/S0002-9440(10)64493-8

61. Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, Prasad AN, Fenton KA, Yu H, Fouts TR, Broder CC. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. NAP. Vaccines. 2021 Feb 8; 6(1): 23. DOI: 10.1038/s41541-021- 00284-w

62. Verma MK, Verma P, Singh S, Gaur P, Siddiqui AH, Pandey S. Nipah virus-infectious agent: An overview. Int. J. Life. Sci. Scienti. Res. eISSN. 2018; 2455(1716): 1716. Doi: 10.1080/01652176.2019.1580827

63. Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Research. 2013 Oct 1; 100(1): 8-13. Doi: 10.1016/j.antiviral.2013.06.012

64. Alofi M. Hendra and Nipah infection: emerging paramyxoviruses. Virus Research. 2013 Nov 6; 177(2): 119-26. DOI: 10.1016/j.virusres.2013.08.002

65. o MK, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Scholte FE, Shrivastava-Ranjan P, Montgomery JM, Nichol ST, Weissman D, Spyropoulos CF. Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. The Journal of Infectious Diseases. 2020 May 1; 221(Supplement_4): S493-8. DOI: 10.1093/indies/jiz553

66. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Science Translational Medicine. 2012 Aug 8; 4(146): 146ra107-.doi: 10.1126/scitranslmed.3004241

67. Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine. 2016 Jun 3; 34(26): 2971-5. DOI: 10.1016/j.vaccine.2015.12.075

68. Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ. Rhabdovirus-based vaccine platforms against henipaviruses. J Virol. 2015; 89(1): 144-54. Doi: 10.1128/JVI.02308-14

69. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC. Development and registration of recombinant veterinary vaccines: the example of the canarypox vector platform. Vaccine. 2007 Jul 26; 25(30): 5606-12. DOI: 10.1016/j.vaccine.2006.11.066

70. Bonaparte MI, Dimitrov AS, Bossart KN, et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci. 2005; 102: 10652–10657. DOI: 10.1073/pnas.0504887102

71. Ploquin A, Szécsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT, Cosset FL, Horvat B, Salvetti A. Protection against henipaviral infection by use of recombinant adeno-associated virus–vector vaccines. The Journal of Infectious Diseases. 2013 Feb 1; 207(3): 469-78. DOI: 10.1093/infdis/jis699

72. Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PloS one. 2013 Mar 14; 8(3): e58414. Doi: 10.1371/journal.pone.0058414

73. Walpita P, Cong Y, Jahrling PB, Rojas O, Postnikova E, Yu S, Johns L, Holbrook MR. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines. 2017 Aug 8; 2(1): 21. DOI: 10.1038/s41541-017-0023-7

Received on 16.04.2024 Modified on 05.06.2024

Asian J. Pharm. Res. 2024; 14(3):295-302.

DOI: 10.52711/2231-5691.2024.00046